Rigel Pharmaceuticals, Inc. (RIGL)

1.5500 -0.0100 (-0.64%) As of 03:20PM EDT. Market open.

Rigel Pharmaceuticals, Inc.

1180 Veterans Boulevard
South San Francisco, CA 94080
United States
650 624 1100
https://www.rigel.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 165

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Raul R. Rodriguez	Pres, CEO & Director	979.34k	N/A	1961
Mr. Dean L. Schorno CPA	Exec. VP & CFO	623.46k	N/A	1963
Ms. Dolly A. Vance	Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec.	810.06k	N/A	1965
Dr. Wolfgang Dummer M.D., Ph.D.	Exec. VP & Chief Medical Officer	644.05k	N/A	1966
Mr. David A. Santos	Exec. VP & Chief Commercial Officer	600.64k	N/A	1963
Mr. Joseph Lasaga	Exec. VP of Corp. Devel.	N/A	N/A	1975
Ms. Julie Patel	Sr. VP of HR	N/A	N/A	N/A
Dr. Esteban S. Masuda	Exec. VP of Research	N/A	N/A	1962
Mr. Tarek Sallam	VP of Marketing	N/A	N/A	N/A

Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Corporate Governance

Rigel Pharmaceuticals, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 5. The pillar scores are Audit: 5; Board: 6; Shareholder Rights: 3; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.